Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy

被引:18
作者
Sugimoto, Mitsushige [1 ]
Nishino, Masafumi [2 ]
Kodaira, Chise [2 ]
Yamade, Mihoko [2 ]
Uotani, Takahiro [2 ]
Ikuma, Mutsuhiro [2 ]
Umemura, Kazuo [3 ]
Furuta, Takahisa
机构
[1] Hamamatsu Univ Sch Med, Clin Res Ctr, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan
[2] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
[3] Hamamatsu Univ Sch Med, Dept Pharmacol, Hamamatsu, Shizuoka 4313192, Japan
关键词
Non-erosive reflux disease; Rabeprazole; CYP2C19; GASTRIC-ACID INHIBITION; JAPANESE PATIENTS; SYMPTOM RELIEF; EROSIVE ESOPHAGITIS; HELICOBACTER-PYLORI; GENOTYPE STATUS; DOUBLE-BLIND; RABEPRAZOLE; OMEPRAZOLE; EFFICACY;
D O I
10.3748/wjg.v17.i14.1858
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate whether potent acid inhibition is effective in non-erosive reflux disease (NERD) refractory to standard rabeprazole (RPZ) treatment. METHODS: We treated 10 Japanese patients with NERD resistant to standard dosages of RPZ: 10 mg or 20 mg od, 20 mg bid, or 10 mg qid for 14 days. All patients completed a frequency scale for symptoms of gastroesophageal reflux disease questionnaire frequency scale for the symptoms of GERD (FSSG); and underwent 24 h pH monitoring on day 14. RESULTS: With increased dosages and frequency of administration of RPZ, median intragastric pH significantly increased, and FSSG scores significantly decreased. With RPZ 10 mg qid, potent acid inhibition was attained throughout 24 h. However, five subjects were refractory to RPZ 10 mg qid, although the median intragastric pH in these subjects (6.6, range: 6.2-7.1) was similar to that in the remaining five responsive subjects (6.5, range: 5.3-7.3). With baseline RPZ 10 mg od, FSSG scores in responsive patients improved by > 30%, whereas there was no significant decrease in the resistant group. CONCLUSION: NERD patients whose FSSG score fails to decrease by > 30% after treatment with RPZ 10 mg od for 14 d are refractory to higher dosage. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:1858 / 1865
页数:8
相关论文
共 37 条
[1]   Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole [J].
Adachi, K ;
Hashimoto, T ;
Hamamoto, N ;
Hirakawa, K ;
Niigaki, M ;
Miyake, T ;
Taniura, H ;
Ono, M ;
Kaji, T ;
Suetsugu, H ;
Yagi, J ;
Komazawa, Y ;
Mihara, T ;
Katsube, T ;
Fujishiro, H ;
Shizuku, T ;
Hattori, S ;
Yamamoto, S ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (12) :1392-1398
[2]   The endoscopic assessment of esophagitis: A progress report on observer agreement [J].
Armstrong, D ;
Bennett, JR ;
Blum, AL ;
Dent, J ;
deDombal, FT ;
Galmiche, JP ;
Lundell, L ;
Margulies, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GASTROENTEROLOGY, 1996, 111 (01) :85-92
[3]   Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis [J].
Bate, CM ;
Green, JRB ;
Axon, ATR ;
Murray, FE ;
Tildesley, G ;
Emmas, CE ;
Taylor, MD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (04) :755-763
[4]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[5]   Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis [J].
Chiba, N ;
DeGara, CJ ;
Wilkinson, JM ;
Hunt, RH .
GASTROENTEROLOGY, 1997, 112 (06) :1798-1810
[6]   Updated guidelines for the diagnosis and treatment of Gastroesophageal reflux disease [J].
DeVault, KR ;
Castell, DO .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (01) :190-200
[7]  
Fass R, 2001, AM J GASTROENTEROL, V96, P303
[8]  
Fass R, 2002, AM J GASTROENTEROL, V97, P1901
[9]   Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease [J].
Fass, R .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :S2-S7
[10]   Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia [J].
Fock, K. M. ;
Teo, E. K. ;
Ang, T. L. ;
Chua, T. S. ;
Ng, T. M. ;
Tan, Y. L. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (20) :3091-3098